Search Results

A recent case report of a woman whose stomach mass was dissolved with diet soda has renewed attention on a rare side effect of GLP-1 weight-loss drugs

Experimental triple-hormone therapy achieved up to 24.2% weight loss in Phase 2 trials, but it remains under investigation and is not yet FDA approved.

How weight-loss drugs like GLP-1 agonists may influence the brain’s reward system and addictive behaviours.

GLP-1 drugs may help treat more than obesity, but research is still evolving.

GLP-1 drugs may help people with brain metastases and diabetes live longer.

FDA inspection finds safety reporting gaps at Novo Nordisk involving serious adverse events linked to widely used GLP-1 diabetes and obesity drugs